{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:52:51Z","timestamp":1773298371879,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","nwhjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nursing for Women's Health"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1111\/1751-486x.12216","type":"journal-article","created":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T13:10:34Z","timestamp":1439298634000},"page":"298-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Helping Women Understand Treatment Options for Vulvar and Vaginal Atrophy"],"prefix":"10.1016","volume":"19","author":[{"given":"Diane M.","family":"Parks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4 Suppl","key":"10.1111\/1751-486X.12216_bb0010","first-page":"1S","article-title":"Executive summary","volume":"104","year":"2004","journal-title":"Obstetrics and Gynecology"},{"issue":"4 Suppl","key":"10.1111\/1751-486X.12216_bb0015","first-page":"128S","article-title":"Summary of balancing risks and benefits","volume":"104","year":"2004","journal-title":"Obstetrics and Gynecology"},{"issue":"4","key":"10.1111\/1751-486X.12216_bb0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1471-0528.1996.tb09741.x","article-title":"A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy","volume":"103","author":"Ayton","year":"1996","journal-title":"British Journal of Obstetrics and Gynaecology"},{"issue":"4","key":"10.1111\/1751-486X.12216_bb0025","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/gme.0b013e3181a48c4e","article-title":"Efficacy and safety of low\u2010dose regimens of conjugated estrogens cream administered vaginally","volume":"16","author":"Bachmann","year":"2009","journal-title":"Menopause"},{"issue":"Suppl. 1","key":"10.1111\/1751-486X.12216_bb0030","first-page":"92","article-title":"Efficacy of ospemifene when used in the treatment of vulvar and vaginal atrophy for up to 52 weeks in postmenopausal women","volume":"14","author":"Bachmann","year":"2011","journal-title":"Climacteric"},{"issue":"3","key":"10.1111\/1751-486X.12216_bb0035","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: Results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"issue":"3","key":"10.1111\/1751-486X.12216_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005237-199512000-00004","article-title":"The role of the nurse practitioner in ambulatory women's health","volume":"9","author":"Barron","year":"1995","journal-title":"Journal of Perinatal and Neonatal Nursing"},{"issue":"6","key":"10.1111\/1751-486X.12216_bb0045","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/09513591003632258","article-title":"Low\u2010dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: A preliminary study","volume":"26","author":"Biglia","year":"2010","journal-title":"Gynecological Endocrinology"},{"issue":"3","key":"10.1111\/1751-486X.12216_bb0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0378-5122(95)00955-8","article-title":"Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women","volume":"23","author":"Bygdeman","year":"1996","journal-title":"Maturitas"},{"key":"10.1111\/1751-486X.12216_bb0055","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.steroids.2014.07.012","article-title":"Ospemifene: A first\u2010in\u2010class, non\u2010hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy","volume":"90","author":"DeGregorio","year":"2014","journal-title":"Steroids"},{"issue":"6","key":"10.1111\/1751-486X.12216_bb0060","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1745-7599.2011.00618.x","article-title":"The evolution of specialists in women's health care across the lifespan: Women's health nurse practitioners","volume":"23","author":"Fontenot","year":"2011","journal-title":"Journal of the American Academy of Nurse Practitioners"},{"issue":"4","key":"10.1111\/1751-486X.12216_bb0065","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2217\/WHE.14.29","article-title":"Perceptions of dyspareunia in postmenopausal women with vulvar and vaginal atrophy: Findings from the REVIVE survey","volume":"10","author":"Freedman","year":"2014","journal-title":"Womens Health (London, England)"},{"issue":"11","key":"10.1111\/1751-486X.12216_bb0070","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1097\/gme.0b013e3182227ebd","article-title":"Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative","volume":"18","author":"Gass","year":"2011","journal-title":"Menopause"},{"key":"10.1111\/1751-486X.12216_bb0075","series-title":"Age and sex composition: 2010 (C2010BR\u201003)","author":"Howden","year":"2011"},{"issue":"3","key":"10.1111\/1751-486X.12216_bb0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1155\/2008\/269571","article-title":"Dyspareunia in postmenopausal women: A critical review","volume":"13","author":"Kao","year":"2008","journal-title":"Pain Research and Management"},{"issue":"3","key":"10.1111\/1751-486X.12216_bb0085","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cnur.2009.06.006","article-title":"A historical perspective of the women's health nurse practitioner","volume":"44","author":"Kass\u2010Wolff","year":"2009","journal-title":"Nursing Clinics of North America"},{"issue":"4","key":"10.1111\/1751-486X.12216_bb0090","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1111\/1751-486X.12216_bb0095","first-page":"105","article-title":"Treating dyspareunia caused by vaginal atrophy: A review of treatment options using vaginal estrogen therapy","volume":"1","author":"Kingsberg","year":"2010","journal-title":"International Journal of Women's Health"},{"issue":"7","key":"10.1111\/1751-486X.12216_bb0100","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jsm.12190","article-title":"Vaginal atrophy in postmenopausal women: Findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey","volume":"10","author":"Kingsberg","year":"2013","journal-title":"Journal of Sexual Medicine"},{"issue":"4","key":"10.1111\/1751-486X.12216_bb0105","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/AOG.0b013e3182118790","article-title":"Vaginal pH\u2010balanced gel for the control of atrophic vaginitis among breast cancer survivors: A randomized controlled trial","volume":"117","author":"Lee","year":"2011","journal-title":"Obstetrics and Gynecology"},{"issue":"1","key":"10.1111\/1751-486X.12216_bb0110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.fertnstert.2005.06.042","article-title":"A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women","volume":"85","author":"Long","year":"2006","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1111\/1751-486X.12216_bb0115","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvovaginal atrophy","volume":"85","author":"Mac Bride","year":"2010","journal-title":"Mayo Clinic Proceedings"},{"issue":"5","key":"10.1111\/1751-486X.12216_bb0120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1447-0756.2001.tb01266.x","article-title":"The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: A comparative study","volume":"27","author":"Manonai","year":"2001","journal-title":"Journal of Obstetrics and Gynaecology Research"},{"issue":"1","key":"10.1111\/1751-486X.12216_bb0125","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0015-0282(16)56474-7","article-title":"Comparative study: Replens versus local estrogen in menopausal women","volume":"61","author":"Nachtigall","year":"1994","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1111\/1751-486X.12216_bb0130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.maturitas.2010.08.001","article-title":"Women's voices in the menopause: Results from an international survey on vaginal atrophy","volume":"67","author":"Nappi","year":"2010","journal-title":"Maturitas"},{"issue":"1","key":"10.1111\/1751-486X.12216_bb0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/13697137.2011.647840","article-title":"Vaginal health: Insights, views & attitudes (VIVA) \u2014Results from an international survey","volume":"15","author":"Nappi","year":"2012","journal-title":"Climacteric"},{"issue":"3","key":"10.1111\/1751-486X.12216_bb0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/gme.0b013e31824b970a","article-title":"The 2012 hormone therapy position statement of: The North American Menopause Society","volume":"19","year":"2012","journal-title":"Menopause"},{"key":"10.1111\/1751-486X.12216_bb0145","unstructured":"North American Menopause Society. (2013a). Menopause glossary. Mayfield Heights, OH. Retrieved from www.menopause.org\/for\u2010women\/menopause\u2010glossary"},{"issue":"9","key":"10.1111\/1751-486X.12216_bb0150","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/GME.0b013e3182a122c2","article-title":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society","volume":"20","year":"2013","journal-title":"Menopause"},{"key":"10.1111\/1751-486X.12216_bb0155","unstructured":"Novo Nordisk. (2012). Data reveal the negative emotional and physical impact that a silent symptom of menopause has on U.S. women and their partners (press release). Retrieved from press.novonordisk\u2010us.com\/2012\u201010\u201005\u2010Data\u2010Reveal\u2010the\u2010Negative\u2010Emotional\u2010and\u2010Physical\u2010Impact\u2010that\u2010a\u2010Silent\u2010Symptom\u2010of\u2010Menopause\u2010Has\u2010on\u2010U.S.\u2010Women\u2010and\u2010Their\u2010Partners"},{"key":"10.1111\/1751-486X.12216_bb0160","unstructured":"Pfizer Pharmaceuticals. (2011). Healthy Women Survey. Retrieved from www.healthywomen.org\/content\/press\u2010release\/new\u2010survey\u2010reports\u2010some\u2010postmenopausal\u2010women\u2010endure\u2010vaginal\u2010and\u2010sexual\u2010symptom"},{"issue":"6","key":"10.1111\/1751-486X.12216_bb0165","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/gme.0b013e318279ba64","article-title":"Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy","volume":"20","author":"Portman","year":"2013","journal-title":"Menopause"},{"issue":"12","key":"10.1111\/1751-486X.12216_bb0170","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/jsm.12686","article-title":"Genitourinary syndrome of menopause: Ew terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society","volume":"11","author":"Portman","year":"2014","journal-title":"Journal of Sexual Medicine"},{"issue":"3","key":"10.1111\/1751-486X.12216_bb0175","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00042192-200007030-00005","article-title":"17 beta\u2010estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis","volume":"7","author":"Rioux","year":"2000","journal-title":"Menopause"},{"issue":"3","key":"10.1111\/1751-486X.12216_bb0180","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00042192-200205000-00006","article-title":"Treatment of urogenital atrophy with low\u2010dose estradiol: Preliminary results","volume":"9","author":"Santen","year":"2002","journal-title":"Menopause"},{"issue":"8","key":"10.1111\/1751-486X.12216_bb0185","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1743-6109.2009.01335.x","article-title":"Prevalence and impact of vaginal symptoms among postmenopausal women","volume":"6","author":"Santoro","year":"2009","journal-title":"Journal of Sexual Medicine"},{"key":"10.1111\/1751-486X.12216_bb0190","unstructured":"Shionogi, Inc. (2013). Osphena\u00ae [Package insert]. Florham Park, NJ."},{"issue":"Suppl. 1","key":"10.1111\/1751-486X.12216_bb0195","first-page":"87","article-title":"Evaluation of the safety of daily ospemifene 60 mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women (abstract)","volume":"14","author":"Simon","year":"2011","journal-title":"Climacteric"},{"issue":"4","key":"10.1111\/1751-486X.12216_bb0200","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"One\u2010year long\u2010term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"issue":"3","key":"10.1111\/1751-486X.12216_bb0205","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/AOG.0b013e318265df42","article-title":"A sustained decline in postmenopausal hormone use: Results from the National Health and Nutrition Examination Survey, 1999\u20132010","volume":"120","author":"Sprague","year":"2012","journal-title":"Obstetrics and Gynecology"},{"issue":"1","key":"10.1111\/1751-486X.12216_bb0210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/gme.0b013e31821f92df","article-title":"Management of vulvovaginal atrophy\u2010related sexual dysfunction in postmenopausal women: An up\u2010to\u2010date review","volume":"19","author":"Tan","year":"2012","journal-title":"Menopause"},{"key":"10.1111\/1751-486X.12216_bb0215","unstructured":"Warner Chilcott. (2005). Femring\u00ae [Package insert]. Rockaway, NJ."},{"key":"10.1111\/1751-486X.12216_bb0220","unstructured":"Warner Chilcott. (2011). ESTRACE\u00ae cream [Package insert]. Rockaway, NJ."},{"issue":"6","key":"10.1111\/1751-486X.12216_bb0225","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1751-486X.2012.01776.x","article-title":"An overview of chronic vaginal atrophy and options for symptom management","volume":"16","author":"Woods","year":"2012","journal-title":"Nursing for Women's Health"},{"issue":"3","key":"10.1111\/1751-486X.12216_bb0230","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.maturitas.2012.12.002","article-title":"Ospemifene, vulvovaginal atrophy, and breast cancer","volume":"74","author":"Wurz","year":"2013","journal-title":"Maturitas"},{"key":"10.1111\/1751-486X.12216_bb0235","series-title":"Surveys of postmenopausal women and health care professionals who treat postmenopausal women","article-title":"REVEAL: REvealing Vaginal Effects at mid\u2010Life","author":"Wyeth","year":"2009"},{"key":"10.1111\/1751-486X.12216_bb0240","first-page":"23","article-title":"Management of vaginal atrophy: Implications from the REVIVE Survey","volume":"8","author":"Wysocki","year":"2014","journal-title":"Clinical Medicine Insights: Reproductive Health"}],"container-title":["Nursing for Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S175148511530012X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S175148511530012X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T21:41:27Z","timestamp":1761687687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S175148511530012X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S175148511530012X"],"URL":"https:\/\/doi.org\/10.1111\/1751-486x.12216","relation":{},"ISSN":["1751-4851"],"issn-type":[{"value":"1751-4851","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Helping Women Understand Treatment Options for Vulvar and Vaginal Atrophy","name":"articletitle","label":"Article Title"},{"value":"Nursing for Women's Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/1751-486X.12216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 AWHONN. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}